Delivery Order EPD13055-0004

Award Date 4/25/16
Potential Completion Date 10/21/16
Potential Value $292K
Ultimate Awardee
Not listed
Set-Aside Type
Total Small Business
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Madison, WI 53719, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
5
Legislative Mandate
Clinger Cohen Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency, to Stemina Biomarker Discovery, Inc., a for-profit organization. The contract, valued at $999,936.00, is a definitive, cost-plus-fixed-fee contract set aside for small businesses. The contract involves services related to Stemina's DevTox QuickPredict assay, a human pluripotent stem cell-based assay that uses a biomarker ratio to predict developmental toxicity potential. Through this contract, Stemina...
<p>This is a $473,343.79 firm fixed price delivery order contract awarded to Odyssey Thera, Inc., a small disadvantaged business, by the U.S. Environmental Protection Agency's Office of Research and Development. The contract is for EDSP ToxCast Phase IV work, which is part of the EPA's Endocrine Disruptor Screening Program. The order was placed under an existing contract and has an ultimate completion date of October 13, 2015. The contract does not have a set-aside designation.</p>
This is a firm fixed price delivery order awarded by the Environmental Protection Agency's Office of Research and Development to Evotec US Inc., a foreign-owned, for-profit organization. The order, valued at $399,804.80, is for toxicology data generation services under the ToxCast chemical prioritization program, including chemical procurement, analysis, sample preparation, and management. Evotec has provided similar services to the EPA under several prior delivery orders against the larger...
<p>This is a task order awarded under contract EP-D-13-009 to Acea Biosciences, Inc., a small business, by the U.S. Environmental Protection Agency's Office of Research and Development. The task order, valued at $415,402.00, is for the identification of estrogen receptor agonists as part of the TOXCAST microelectronic monitoring of cellular status program. The contract is a firm fixed price delivery order.</p>
This is a $171,718.85 firm fixed-price delivery order contract awarded by the U.S. Environmental Protection Agency's (EPA) Office of Research and Development to Evotec US Inc., a foreign-owned, for-profit organization. The contract, which was set aside for small businesses, is for chemical procurement, analysis, sample preparation, and management services to support the EPA's ToxCast chemical screening program. Evotec has previously received multiple task orders from the EPA's $16,123,957.10...
This is a firm fixed-price delivery order under the EPA's $7.8 million indefinite delivery contract (IDC) awarded to Integrated Laboratory Systems, LLC (ILS), a small business contractor. The delivery order, valued at $381,371.82, is for ILS to conduct mammalian oral exposure studies at EPA facilities to support the agency's Center for Computational Toxicology and Exposure. This work contributes data on chemical exposure pathways to inform the EPA's regulatory programs and mission to protect...
<p>This is a firm fixed-price delivery order contract awarded by the U.S. Environmental Protection Agency's Office of Research and Development to Aruna Bio Inc. for developmental toxicity models in support of the ToxCast program. The contract has a total ceiling value of $186,262.70 and a period of performance ending on July 19, 2018. The contract was awarded on February 5, 2016 and does not have a set-aside designation. Aruna Bio Inc. is the prime contractor for this award.</p>
This is a firm-fixed-price task order awarded by the U.S. Environmental Protection Agency's (EPA) Office of Research and Development to Evotec US Inc., a foreign-owned, for-profit organization, for chemical procurement, analysis, sample preparation, and management services. The task order, valued at $399,848.75, was issued under the company's larger $16,123,957.10 single-award Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the EPA to support the agency's ToxCast chemical...
This is a $233,349.20 firm fixed price delivery order contract awarded by the Environmental Protection Agency's (EPA) Office of Research and Development to Evotec US Inc., a foreign-owned for-profit organization. The contract is for chemical procurement, analysis, sample preparation, and management services in support of the EPA's ToxCast chemical prioritization program. This delivery order is one of several issued to Evotec by the EPA since 2019 under contract 68HE0D18D0001, ranging from...
This is a Delivery Order awarded by the Environmental Protection Agency (EPA) to Eurofins Discovery Services North America, LLC, a foreign-owned, for-profit contract research organization, under the EPA's $9.7 million Indefinite Delivery Vehicle (IDV) contract for in vitro and target-based assays through December 2026. The Delivery Order, valued at $250,054.90, is for the &quot;INITIATION OF INTERNAL TO 7 TO ACQUIRE ASSAYS PER THE ORDER DETAILS.&quot; This is a Firm Fixed Price contract with...
  • EPD13055
    Indefinite Delivery Contract
  • EPD13055-0004
    Delivery Order

This is a firm fixed-price delivery order awarded by the Office of Research and Development, a civilian agency within the Environmental Protection Agency (EPA), to Stemina Biomarker Discovery, Inc., a small business prime contractor. The $291,515.94 contract is for the DEVELOPMENTAL TOXICITY MODELS - STEMINA TASK ORDER 4 EPD13055 project, which involves providing services related to Stemina's DevTox QuickPredict assay, a human pluripotent stem cell-based test that can predict developmental toxicity potential. The contract has a total small business set-aside designation. Stemina Biomarker Discovery has previously received a cooperative agreement from the U.S. Food and Drug Administration (FDA) to support efforts to qualify the DevTox QuickPredict assay through the FDA's Biomarker Qualification Program, which could reduce animal testing and provide a more human-relevant approach to assessing developmental toxicity safety.

Generated 4/2/25, 4:36 PM